{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:33:58Z","timestamp":1790087638370,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011284","name":"Valeant Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022336","name":"Esperion Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015993","name":"Kowa Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jacl.2020.08.009","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T23:46:14Z","timestamp":1599003974000},"page":"649-659.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials"],"prefix":"10.1016","volume":"14","author":[{"given":"Harold E.","family":"Bays","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Barton","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Antonio M.","family":"Gotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. B. John","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LeAnne T.","family":"Bloedon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sasiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9753","key":"10.1016\/j.jacl.2020.08.009_bib1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jacl.2020.08.009_bib2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","article-title":"Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis","volume":"3","author":"Sabatine","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"39","key":"10.1016\/j.jacl.2020.08.009_bib3","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.jacl.2020.08.009_bib4","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2020.08.009_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jacl.2013.09.009","article-title":"Therapeutic practice patterns related to statin potency and ezetimibe\/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease","volume":"8","author":"Toth","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2020.08.009_bib6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.clinthera.2017.03.001","article-title":"Use of lipid-modifying therapy and LDL-C goal attainment in a high-cardiovascular-risk population in the Netherlands","volume":"39","author":"Kuiper","year":"2017","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.jacl.2020.08.009_bib7","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART Registry follow-up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2020.08.009_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","author":"De Backer","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2020.08.009_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1567-5688(17)30024-7","article-title":"Practical aspects in the management of statin-associated muscle symptoms (SAMS)","volume":"26","author":"Laufs","year":"2017","journal-title":"Atheroscler Suppl"},{"issue":"10","key":"10.1016\/j.jacl.2020.08.009_bib10","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","article-title":"Optimizing Cholesterol Treatment in Patients With Muscle Complaints","volume":"70","author":"Rosenson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2020.08.009_bib11","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacl.2020.08.009_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.jacl.2020.08.009_bib13","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacl.2020.08.009_bib14","doi-asserted-by":"crossref","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"10.1016\/j.jacl.2020.08.009_bib15","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: The CLEAR Wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2020.08.009_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia","author":"Banach","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2020.08.009_bib17","series-title":"NEXLETOL (bempedoic acid) [package insert]","year":"2020"},{"issue":"7","key":"10.1016\/j.jacl.2020.08.009_bib18","doi-asserted-by":"crossref","first-page":"e1003121","DOI":"10.1371\/journal.pmed.1003121","article-title":"Lipid and Blood Pressure Meta-Analysis Collaboration Group, the International Lipid Expert Panel. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis","volume":"17","author":"Cicero","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacl.2020.08.009_bib19","doi-asserted-by":"crossref","DOI":"10.1007\/s40264-020-00931-6","article-title":"Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies","author":"Cicero","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.jacl.2020.08.009_bib20","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials","author":"Dai","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2020.08.009_bib21","doi-asserted-by":"crossref","DOI":"10.1007\/s40256-020-00399-w","article-title":"A review of the efficacy and tolerability of bempedoic acid in the treatment of hypercholesterolemia","author":"Niman","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"issue":"7","key":"10.1016\/j.jacl.2020.08.009_bib22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/14779072.2020.1782744","article-title":"Bempedoic acid for the treatment of hypercholesterolemia","volume":"18","author":"Yang","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jacl.2020.08.009_bib23","series-title":"LIPITOR (atorvastatin) [package insert]","year":"2019"},{"key":"10.1016\/j.jacl.2020.08.009_bib24","series-title":"CRESTOR (rosuvastatin) [package insert]","year":"2010"},{"key":"10.1016\/j.jacl.2020.08.009_bib25","series-title":"ZOCOR (simvastatin) [package insert]","year":"2020"},{"key":"10.1016\/j.jacl.2020.08.009_bib26","series-title":"Zetia (ezetimibe) [package insert]","year":"2013"},{"issue":"24","key":"10.1016\/j.jacl.2020.08.009_bib27","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"issue":"9716","key":"10.1016\/j.jacl.2020.08.009_bib28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2020.08.009_bib29","first-page":"A11417","article-title":"Abstract 11417: Bempedoic acid and glycemic control: a pooled analysis of 4 phase 3 clinical trials","volume":"140","author":"Leiter","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2020.08.009_bib30","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1248\/bpb.33.498","article-title":"Renal secretion of uric acid by organic anion transporter 2 (OAT2\/SLC22A7) in human","volume":"33","author":"Sato","year":"2010","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"10.1016\/j.jacl.2020.08.009_bib31","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/ki.2014.66","article-title":"Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat","volume":"86","author":"Lepist","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacl.2020.08.009_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jot.2018.07.003","article-title":"Tendon pathology in hypercholesterolaemia patients: Epidemiology, pathogenesis and management","volume":"16","author":"Yang","year":"2019","journal-title":"J Orthop Translat"},{"issue":"5","key":"10.1016\/j.jacl.2020.08.009_bib33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MJT.0000000000000039","article-title":"Is statin use associated with tendon rupture? a population-based retrospective cohort analysis","volume":"22","author":"Contractor","year":"2015","journal-title":"Am J Ther"},{"issue":"8","key":"10.1016\/j.jacl.2020.08.009_bib34","doi-asserted-by":"crossref","first-page":"e42866","DOI":"10.1371\/journal.pone.0042866","article-title":"A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class","volume":"7","author":"Hoffman","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jacl.2020.08.009_bib35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/art.23309","article-title":"Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature","volume":"59","author":"Marie","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jacl.2020.08.009_bib36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.amjcard.2007.02.068","article-title":"Tendon rupture associated with simvastatin\/ezetimibe therapy","volume":"100","author":"Pullatt","year":"2007","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2020.08.009_bib37","first-page":"185","article-title":"Bilateral, simultaneous rupture of the quadriceps tendon associated with simvastatin","volume":"13","author":"Rubin","year":"2011","journal-title":"Isr Med Assoc J"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420302543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420302543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:36:04Z","timestamp":1761831364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287420302543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1933287420302543"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2020.08.009","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2020.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}